PMN · ProMIS Neurosciences Inc. · Executive Compensation
Market Cap
$101.07M
Shares
8.97M
Volume · Oct 5
38.21K
Avg daily vol (3M)
85.51K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gail Farfel | CEO | $1,017,163 |
| Eugene Williams | Chairman & Former CEO | $683,137 |
| Neil Cashman | Chief Scientific Officer | $577,724 |
| Gavin Malenfant | Chief Operating Officer | $413,489 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gavin Malenfant | Chief Operating Officer | $430,383 |
| Eugene Williams | Chairman & Former CEO | $381,057 |
| Neil Cashman | Chief Scientific Officer | $79,017 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Slanix Alex, Pharm.D | director | Appointed | 2026-05-20 |
| William Wyman | director | Appointed | 2026-05-20 |
| Joshua Mandel-Brehm | director | Appointed | 2026-05-20 |
| Neil K. Warma | director | Appointed | 2026-05-20 |
| Maggie Shafmaster, Ph.D., J.D. | director | Appointed | 2026-05-20 |
| Neil Cashman, M.D. | director | Appointed | 2026-05-20 |
| Eugene Williams | director | Appointed | 2026-05-20 |
| Slanix Paul Alex | director | Appointed | 2025-10-24 |
| Gavin T. Malenfant | Chief Operating Officer | Terminated | 2025-02-19 |
| Neil Warma | President and Chief Executive Officer | Appointed | 2024-10-10 |
| Gail Farfel, Ph.D. | member of the Board of Directors | Terminated | 2024-01-03 |
| Neil Warma | President and interim Chief Executive Officer and principal executive officer | Appointed | 2024-01-03 |
| Gail Farfel, Ph.D. | President and Chief Executive Officer and principal executive officer | Terminated | 2024-01-03 |
| Gail M. Farfel | Chief Executive Officer | Appointed | 2022-09-13 |
| Gail Farfel | Chief Executive Officer | Appointed | 2022-09-13 |